Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $2.69B | $2.83B | $2.81B | $2.73B |
| Revenue growth | — | 5.1% | -0.7% | -2.5% |
| Operating income | $192M | $218M | $158M | $64.4M |
| Operating margin | 7.2% | 7.7% | 5.6% | 2.4% |
| Net income | $142M | $213M | $21.0M | -$40.2M |
| Net margin | 5.3% | 7.5% | 0.7% | -1.5% |
| EPS (diluted) | $1.08 | $1.63 | $0.16 | -$0.31 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | $233M | $257M | $472M | $64.2M |
| Capital expenditures | $76.4M | $77.9M | $78.9M | $58.5M |
| Free cash flow | $156M | $179M | $393M | $5.77M |
| Dividends paid | $0.00 | $0.00 | $13.8M | $13.8M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $23.7M | $36.1M | $31.0M | $29.7M |
| Total assets | — | $3.16B | $2.93B | $2.91B |
| Total liabilities | — | $2.28B | $2.03B | $2.04B |
| Long-term debt | — | $1.46B | $1.15B | $1.16B |
| Shareholders' equity | $2.34B | $877M | $903M | $866M |
| Retained earnings | — | $0.00 | $2.56M | -$46.9M |
| Shares (wtd avg diluted) | 131M | 131M | 132M | 132M |
Every figure is extracted from Vestis Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.